Journal of the American Veterinary Medical Association · 2026
Retrospective evaluation of canine parvovirus monoclonal antibody supports faster clinical recovery in shelter dogs with naturally occurring canine parvovirus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Welton Molly, Hadden Hayley, Herron Meghan, Winston Jenessa A
Аннотация
OBJECTIVE: To retrospectively evaluate the clinical efficacy and safety of the canine parvovirus monoclonal antibody (CPMA) administered with standardized supportive care for naturally occurring canine parvovirus (CPV) in a shelter setting.
METHODS: Electronic medical records from CPV-positive dogs treated at Gigi's Parvovirus Treatment Center between June 2020 and May 2024 were reviewed. All dogs received a standardized standard-of-care (SOC) algorithm. Dogs treated prior to August 2023 received SOC alone (n = 49), while those admitted thereafter received CPMA (0.2 mL/kg, IV) plus SOC (63). Primary outcomes were hospitalization duration, mortality, and time to isolation release criteria (2 consecutive negative CPV ELISA tests [SNAP; Idexx Laboratories Inc]). Secondary outcomes included modified clinical severity scores, medication scores, and total cost of care.
RESULTS: Dogs receiving CPMA with SOC had significantly shorter hospitalization (median, 2 vs 4 days) and reached isolation release criteria sooner (median, 5 vs 6.5 days) compared with SOC alone. Mortality did not differ significantly (17% vs 22%). Maximum medication scores and overall cost of care were not statistically different, although CPMA-treated dogs showed a real-world median cost reduction of $978.50. One CPMA-treated dog experienced an anaphylactic reaction and recovered with supportive care.
CONCLUSIONS: CPMA administration in combination with SOC accelerated clinical recovery and time to release from isolation compared with SOC alone.
CLINICAL RELEVANCE: CPMA appears clinically effective and safe for naturally occurring CPV infections in a shelter environment. By reducing isolation time, CPMA may improve welfare, reduce behavioral risk associated with prolonged isolation and medical trauma, and support earlier adoption.
METHODS: Electronic medical records from CPV-positive dogs treated at Gigi's Parvovirus Treatment Center between June 2020 and May 2024 were reviewed. All dogs received a standardized standard-of-care (SOC) algorithm. Dogs treated prior to August 2023 received SOC alone (n = 49), while those admitted thereafter received CPMA (0.2 mL/kg, IV) plus SOC (63). Primary outcomes were hospitalization duration, mortality, and time to isolation release criteria (2 consecutive negative CPV ELISA tests [SNAP; Idexx Laboratories Inc]). Secondary outcomes included modified clinical severity scores, medication scores, and total cost of care.
RESULTS: Dogs receiving CPMA with SOC had significantly shorter hospitalization (median, 2 vs 4 days) and reached isolation release criteria sooner (median, 5 vs 6.5 days) compared with SOC alone. Mortality did not differ significantly (17% vs 22%). Maximum medication scores and overall cost of care were not statistically different, although CPMA-treated dogs showed a real-world median cost reduction of $978.50. One CPMA-treated dog experienced an anaphylactic reaction and recovered with supportive care.
CONCLUSIONS: CPMA administration in combination with SOC accelerated clinical recovery and time to release from isolation compared with SOC alone.
CLINICAL RELEVANCE: CPMA appears clinically effective and safe for naturally occurring CPV infections in a shelter environment. By reducing isolation time, CPMA may improve welfare, reduce behavioral risk associated with prolonged isolation and medical trauma, and support earlier adoption.